Praxis Precision以260美元的价格发行5.75亿美元的股票

2026-01-07 12:48

Clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders, Praxis Precision Medicines (PRAX) priced its underwritten public offering of ~2.2M shares at a public offering price per share of $260.
The gross proceeds from the offering are expected to be approximately $575M.
The underwriters have a 30-day option to purchase up to 331,800 additional shares.
The offering is expected to close on or about January 8, 2026.
The stock price fell 1.8% lower on Tuesday during after-market hours of trading.

More on Praxis Precision Medicines